Global Mouse Nerve Growth Factor Market Size By Type (30μg/Serving, 20μg/Serving), By Application (Injection, Eye Drops), By Region, And Segment Forecasts, 2023 to 2032

The Global Mouse Nerve Growth Factor (mNGF) Market was valued at USD 285 million in 2023 and is projected to reach USD 602 million by 2031, growing at a CAGR of 9.8% during the forecast period from 2023 to 2031. The market is driven by increasing research in neuroscience, rising demand for neurotrophic agents in regenerative medicine, and expanding applications in pharmaceutical and biotechnological industries. Mouse nerve growth factor, a well-characterized neurotrophin, is critical in studying nerve regeneration, neurodegenerative diseases, and central nervous system (CNS) development, fueling its use in both academic and commercial sectors.

Drivers:

1. Increasing Investment in Neurological Research:

The growing global burden of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and multiple sclerosis has spurred investment into research and development. mNGF plays a central role in studying nerve cell survival, differentiation, and repair mechanisms, making it indispensable in neuroscience.

2. Expanding Applications in Biopharmaceuticals:

Mouse NGF is widely used in biopharma research for drug discovery, particularly in studies targeting neuroprotective therapies. Its applications extend to regenerative medicine, where it aids in tissue engineering and cell-based assays.

3. Rising Interest in Cell Culture-Based Assays:

The demand for standardized growth factors in in-vitro and in-vivo cell culture models is increasing, as researchers seek more reliable models for drug efficacy and toxicity testing, supporting broader adoption of mNGF.

Restraints:

1. High Cost of Purification and Production:

Producing recombinant mNGF or purifying it from natural sources involves expensive, complex processes, making it cost-prohibitive for some end-users, particularly in academic settings.

2. Regulatory and Ethical Barriers:

The use of animal-derived proteins in research is increasingly scrutinized under ethical and regulatory frameworks. This may limit its use or require stricter compliance, posing challenges to market expansion.

Opportunity:

1. Advancements in Recombinant Technology:

Ongoing innovations in biotechnology have enabled more cost-effective and scalable production of recombinant mNGF, reducing dependency on animal-derived sources and opening up opportunities for broader commercialization.

2. Growth in Personalized Medicine and Gene Therapy:

The rapid progress in gene therapy and personalized medicine is increasing the demand for molecular tools like mNGF, especially in CNS-targeted interventions and rare neurological conditions.

Market by System Type Insights:

Based on system type, the Recombinant mNGF segment accounted for the largest market share in 2023. Recombinant variants offer consistency, higher purity, and scalable production, making them the preferred choice in pharmaceutical and research settings. The Natural Protein Extracts segment is still relevant for legacy models and smaller research labs, but is expected to decline as recombinant technology becomes more accessible.

Market by End-use Insights:

In 2023, the Pharmaceutical & Biotechnology Companies segment held over 45% of the market share. These firms are heavily investing in CNS research and drug development programs utilizing mNGF. The Academic Research Institutions segment also shows notable growth due to increased government and private funding in neuroscience-related disciplines.

Market by Regional Insights:

North America led the global mouse nerve growth factor market in 2023, supported by its advanced biomedical research infrastructure, strong funding from institutions like the NIH, and presence of major biotech firms. However, Asia-Pacific is projected to grow at the fastest CAGR due to increasing investment in life sciences, growing academic research, and rising incidence of neurodegenerative diseases in countries like China, Japan, and India.

Competitive Scenario:

Key players in the global Mouse Nerve Growth Factor market include Thermo Fisher Scientific, Merck KGaA, Abcam plc, PeproTech Inc., R&D Systems (Bio-Techne), Sino Biological Inc., and ProSpec-Tany TechnoGene Ltd. These companies are investing in R&D, expanding their recombinant protein portfolios, and exploring strategic collaborations to strengthen market presence.

Scope of Work – Global Mouse Nerve Growth Factor Market

Key Market Developments:

2023: Abcam plc launched a next-generation mNGF product line with enhanced bioactivity for stem cell and CNS research applications.

2024: PeproTech (Bio-Techne) expanded its GMP-grade recombinant protein manufacturing capabilities to cater to the growing demand from pharmaceutical clients.

2025: Thermo Fisher Scientific announced a strategic partnership with a neurobiotech start-up to co-develop mNGF-based therapeutics targeting Alzheimer's.

FAQs:

1) What is the current market size of the Global Mouse Nerve Growth Factor Market?

The Global Mouse Nerve Growth Factor Market was valued at USD 285 million in 2023.

2) What is the major growth driver of the Global Mouse Nerve Growth Factor Market?

The primary growth driver is the increasing investment in neuroscience and neurodegenerative disease research.

3) Which is the largest region during the forecast period in the Global Mouse Nerve Growth Factor Market?

North America holds the largest market share, while Asia-Pacific is expected to witness the fastest growth.

4) Which segment accounted for the largest market share in the Global Mouse Nerve Growth Factor Market?

The Recombinant mNGF segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Mouse Nerve Growth Factor Market?

Key players include Thermo Fisher Scientific, Abcam plc, PeproTech Inc., Merck KGaA, and R&D Systems (Bio-Techne).